OXURION®
YOUR VISION IS OUR VISION™

PERSBERICHT

Gereglementeerde informatie

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC

Leuven, BELGIË – 6 november 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving[1], de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 4 november 2026 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 3 november 2026 28.661.021 aandelen van de toen uitstaande 232.004.731 aandelen bezat en dus onder de drempel (15%) kwam door de verkoop van stemrechtverlenende effecten.

Oxurion ontving een transparantiekennisgeving op 5 november 2026 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 6 november 2026 19.086.684 aandelen van de toen uitstaande 232.004.731 aandelen bezat en dus onder de drempel (10%) kwam door de verkoop van stemrechtverlenende effecten.

Over Oxurion

Oxurion NV (Euronext Brussel: OXUR) bouwt een technologisch ondersteund platform voor klinisch onderzoek en software. De Vennootschap combineert expertise in klinische operaties, software-innovatie en operationele data in eigendom om sponsors in de farmaceutische, biotechnologische en medische hulpmiddelensector te ondersteunen. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Voor meer informatie kunt u contact opnemen met:

Oxurion NV
Pascal Ghoson,
Chief Executive Officer
Pascal.ghoson@oxurion.com

1. Art 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

ANNEX 1

FSMA — FINANCIAL SERVICES AND MARKETS AUTHORITY

Transparency notification
Form TR-1 BE
PART I

1) Status of the notification

Final

2) Issuer

Name: OXURION
Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in *part II* concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

03/11/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

15

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

232,004,731

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	41,497,561	28,661,021		12.35%	
	TOTAL	28,661,021	0	12.35%	0.00%

Start with "groups" of holders. Add subtotals with Σ, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on *<CALCULATE>*.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	28,661,021	12.35%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder | will cease to hold / will hold again: 0 | voting rights as of (DD/MM/YYYY)

13) Additional information

On 20 October 2026 (with settlement date on 22 October 2026), Atlas Special Opportunities II LLC sold 11,764,303 shares in Oxurion NV, as a result of which its shareholding decreased to 41,497,561 shares (= 17.887%, denominator = 232,004,731)

On 21 October 2026 (with settlement date on 23 October 2026), Atlas Special Opportunities II LLC sold 319,476 shares in Oxurion NV, as a result of which its shareholding decreased to 41,178,085 shares (= 17.749%, denominator = 232,004,731)

On 23 October 2026 (with settlement date on 27 October 2026), Atlas Special Opportunities II LLC sold 408,977 shares in Oxurion NV, as a result of which its shareholding decreased to 40,769,108 shares (= 17.573%, denominator = 232,004,731)

On 30 October 2026 (with settlement date on 3 November 2026), Atlas Special Opportunities II LLC sold 12,108,087 shares in Oxurion NV, as a result of which its shareholding decreased to 28,661,021 shares (= 12.354%, denominator = 232,004,731)

Done at: New York

On: 03/11/2026 (DD/MM/YYYY)

Name & capacity: Patrick Vance, Proxyholder

Signature: Signed by: 9A8C4789B05442E...

Annex 2

FSMA — FINANCIAL SERVICES AND MARKETS AUTHORITY

Transparency notification
Form TR-1 BE
PART I

1) Status of the notification

Final

2) Issuer

Name	OXURION
Identification number	0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in *part II* concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

06/11/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

232,004,731

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	28,661,021	19,086,684		8.23%	
TOTAL		19,086,684	0	8.23%	0.00%

Start with "groups" of holders. Add subtotals with Σ, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on *<CALCULATE>*.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	19,086,684	8.23%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder		will cease to hold / will hold again	0	voting rights as of (DD/MM/YYYY)	

13) Additional information

On 20 October 2026 (with settlement date on 22 October 2026), Atlas Special Opportunities II LLC sold 11,764,303 shares in Oxurion NV, as a result of which its shareholding decreased to 41,497,561 shares (= 17.887%, denominator = 232,004,731)

On 2 November 2026 (with settlement date on 4 November 2026), Atlas Special Opportunities II LLC sold 941,000 shares in Oxurion NV, as a result of which its shareholding decreased to 27,720,021 shares (= 11.948%, denominator = 232,004,731)

On 3 November 2026 (with settlement date on 5 November 2026), Atlas Special Opportunities II LLC sold 9,000 shares in Oxurion NV, as a result of which its shareholding decreased to 27,711,021 shares (= 11.944%, denominator = 232,004,731)

On 4 November 2026 (with settlement date on 6 November 2026), Atlas Special Opportunities II LLC sold 8,624,337 shares in Oxurion NV, as a result of which its shareholding decreased to 19,086,684 shares (= 8.227%, denominator = 232,004,731)

Done at: New York

On: 06/11/2026 (DD/MM/YYYY)

Name & capacity: Patrick Vance, Proxyholder

Signature: Signed by: 9A8C4789B05442E...